Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00811642
Other study ID # P05551
Secondary ID
Status Completed
Phase Phase 3
First received December 18, 2008
Last updated June 4, 2015
Start date November 2008
Est. completion date March 2010

Study information

Verified date June 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Participants must be 18-70 years male or female

- Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment.

- Sign informed consent form

Exclusion Criteria:

- Female participants who are pregnant or are nursing.

- Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B

- Participants with progressive nervous system diseases( excluding those IFI caused)

- Participants who take the following drugs known with interference with azole antifungal preparations

- terfenadine, cisapride, and ebastine within 24 hours before entry

- astemizole at entry or within 10 days before entry

- cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry

- The drugs listed above are prohibited during the investigation

- Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate <60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.

- Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.

- Expected to take during investigation or is taking systemic antifungal treatment

- Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are >2×ULN.

- Participants expected to survive no more than 72hrs

- Participants receiving artificial aeration and will not withdraw within 24hrs

- Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry.

- Prior enrollment in this study.

- History of alcohol and/or drug abuse.

- Participants cannot be compliant in investigator's opinion.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Posaconazole
400mg BID oral suspension for 12 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Huang X, Wang F, Chen Y, Liu T, Wang J, Hu J, Jie J, Chen F, Wang S, Shen Z, Yu L, Yu K, Liang Y. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of fir — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:
Complete Response: resolution of Invasive Fungal Infection (IFI) attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.
Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.
Stable disease: no progress in IFI attributable symptoms, if present at enrollment.
Failure: deterioration in IFI attributable clinical symptoms.
Treatment week 12 No
Secondary Number of Participants Who Had Clinical Response at 4 Weeks With Posaconazole Treatment EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:
Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.
Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.
Stable disease: no progress in IFI attributable symptoms, if present at enrollment.
Failure: deterioration in IFI attributable clinical symptoms.
Treatment week 4 No
Secondary Number of Participants Who Had Clinical Response at 8 Weeks With Posaconazole Treatment EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:
Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.
Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.
Stable disease: no progress in IFI attributable symptoms, if present at enrollment.
Failure: deterioration in IFI attributable clinical symptoms.
Treatment week 8 No
Secondary Number of Participants With Pathogenic Fungal Eradication at 4 Weeks With Posaconazole Treatment EVALUATION OF FUNGAL ERADICATION:
Participants' mycological response to therapy was assessed by the following:
Eradication: Negative culture or histologically documented absence of infecting
fungal pathogen from a primary site previously positive.
Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.
Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.
Treatment week 4 No
Secondary Number of Participants With Pathogenic Fungal Eradication at 8 Weeks With Posaconazole Treatment EVALUATION OF FUNGAL ERADICATION:
Participants' mycological response to therapy was assessed by the following:
Eradication: Negative culture or histologically documented absence of infecting
fungal pathogen from a primary site previously positive.
Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.
Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.
Treatment week 8 No
Secondary Number of Participants With Pathogenic Fungal Eradication at 12 Weeks With Posaconazole Treatment EVALUATION OF FUNGAL ERADICATION:
Participants' mycological response to therapy was assessed by the following:
Eradication: Negative culture or histologically documented absence of infecting
fungal pathogen from a primary site previously positive.
Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.
Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.
Treatment week 12 No
Secondary Number of Participant Survivors at Week 14 of Post-Posaconazole Treatment Follow-up Total number of participant deaths was assessed at the end of 2 week post-treatment follow-up (14 weeks). The total number of deaths was compared to the number of survivors at baseline. Follow-up week 14 No
See also
  Status Clinical Trial Phase
Completed NCT03641131 - Ampholipad Real-World Data in Taiwan
Not yet recruiting NCT03292224 - Systemic Fungal Infections in ICU Patients N/A
Completed NCT01371656 - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Phase 3
Completed NCT00936117 - Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Phase 2
Completed NCT00740389 - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. Phase 1
Completed NCT03857399 - Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin Phase 2
Not yet recruiting NCT04215458 - Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases N/A
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT02957929 - Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally Phase 1
Completed NCT01419678 - Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients N/A
Recruiting NCT00333645 - Prophylaxis With Caspofungin in High-Risk Liver Transplantation Phase 2
Not yet recruiting NCT03650439 - Fungal Infections in Patients With Hematological Malignancies
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Withdrawn NCT00430469 - Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients Phase 1/Phase 2
Terminated NCT00386997 - ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Phase 4
Completed NCT00514358 - Fluconazole Pharmacokinetics in Infants Phase 1
Completed NCT04166669 - A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 Phase 1
Recruiting NCT05150327 - Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
Completed NCT02387983 - Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) Phase 1
Not yet recruiting NCT06417983 - Topical Application of Essential Oils to Treat Onchomycosis